Log in to save to my catalogue

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a...

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2560959688

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

About this item

Full title

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

Publisher

New York: Nature Publishing Group US

Journal title

Nature medicine, 2021-08, Vol.27 (8), p.1451-1457

Language

English

Formats

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

A randomized, double-blind, placebo-controlled, 52-week study (no. NCT03068468) evaluated gosuranemab, an anti-tau monoclonal antibody, in the treatment of progressive supranuclear palsy (PSP). In total, 486 participants dosed were assigned to either gosuranemab (
n
 = 321) or placebo (
n
 = 165). Efficacy was not demonstrated on adjust...

Alternative Titles

Full title

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2560959688

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2560959688

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X

DOI

10.1038/s41591-021-01455-x

How to access this item